Hermetica Superfood Encyclopedia
The Short Answer
Mkoba contains polyphenolic compounds — principally gallic acid, quercetin, kaempferol, and their glycosides — that exert antioxidant activity through free radical scavenging and antibacterial activity likely through membrane disruption and enzyme inhibition mediated by tannins, terpenoids, and saponins. In rat models, aqueous ethanol leaf extract at 400 mg/kg inhibited carrageenan-induced paw edema by 44.35% and provided 76.83% analgesic protection, with root extracts recording a remarkably potent DPPH IC50 of 0.018 mg/mL.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordMkoba Albizia anthelmintica benefits
Mkoba — botanical close-up
Health Benefits
**Antioxidant Activity**
Root, leaf, and bark extracts of Mkoba demonstrate potent free radical scavenging capacity, with root extracts achieving a DPPH IC50 of 0.018 mg/mL; the isolated compound quercetin-3-O-β-D-glucopyranoside contributes directly with an IC50 of 12.41 µg/mL, driven by the high total phenolic content of 1741.08 mg GAE/100 g in roots.
**Anti-Inflammatory Effects**
Aqueous ethanol leaf extract administered at 200–400 mg/kg in carrageenan-induced edema rat models reduced paw swelling by 37.87–44.35% at 4 hours post-induction, an effect attributed to phenolic compound inhibition of pro-inflammatory mediators such as prostaglandins, approaching the efficacy of the reference drug diclofenac (54.80%).
**Analgesic Properties**: The same aqueous ethanol extract provided 52
44–76.83% analgesic protection in rodent pain models at 200–400 mg/kg, respectively, likely through inhibition of peripheral pain mediator synthesis by flavonoids including quercetin and kaempferol, though central mechanisms have not been ruled out.
**Antibacterial Activity**: Chloroform root extract shows an MIC as low as 0
625 mg/mL against Salmonella enterica, while extracts also inhibit Staphylococcus aureus, Escherichia coli, Shigella sonnei, Clostridium perfringens, Proteus mirabilis, and Serratia marcescens; bioactivity is attributed to tannins, terpenoids, and saponins disrupting bacterial membranes or inhibiting key metabolic enzymes.
**Traditional Anthelmintic Use**
Mkoba has been employed extensively in Tanzanian and broader East African traditional medicine as a treatment for intestinal parasites in both livestock and humans, with the common name itself referencing this anthelmintic application; however, no controlled in vitro or in vivo antiparasitic studies are yet published to confirm the molecular basis of this activity.
**High Phenolic and Flavonoid Density**
Beyond specific activities, Mkoba root extracts contain exceptionally high concentrations of total flavonoids (366.80 mg QE/100 g) alongside total phenolics, providing a broad substrate of bioactive molecules including gallic acid and quercetin glycosides that collectively may support oxidative stress reduction relevant to chronic disease contexts.
**Potential Antimicrobial Spectrum Breadth**
The presence of both Gram-positive (S. aureus, C. perfringens) and Gram-negative (E. coli, S. enterica, P. mirabilis) pathogen inhibition across root, bark, and leaf extracts using multiple solvent systems suggests broad-spectrum antimicrobial potential, though standardized minimum bactericidal concentration data and clinical translation remain absent.
Origin & History
Natural habitat
Albizia anthelmintica is a deciduous tree native to sub-Saharan Africa, distributed across Tanzania, Kenya, Ethiopia, and surrounding East and Southern African nations, typically growing in dry savanna woodlands, bushlands, and semi-arid scrublands at low to mid elevations. The tree thrives in well-drained sandy or loamy soils under full sun and is drought-tolerant, making it well-adapted to the seasonally dry climates of the African interior. It is not widely cultivated commercially; rather, bark, roots, and leaves are harvested from wild populations, raising conservation concerns due to increasing medicinal demand.
“Albizia anthelmintica has been embedded in the traditional medicine systems of Tanzania, Kenya, Ethiopia, and neighboring East African countries for generations, most prominently as a treatment for intestinal worm infestations in both human communities and livestock — a function directly encoded in its Swahili common name 'Mkoba,' which relates to its role in expelling parasites. Traditional healers (waganga) typically prepare decoctions or infusions from the bark and roots, which are administered orally to both children and adults suffering from helminthiasis, with dosing based on empirical knowledge passed through oral tradition rather than written pharmacopoeia. The broader genus Albizia holds significant ethnomedicinal status across Africa and Asia, with several species used in traditional Chinese medicine and Ayurveda for anxiolytic, anthelmintic, and anti-inflammatory purposes, providing phytochemical and pharmacological context for East African uses of A. anthelmintica. Conservation discussions in the scientific literature highlight that increasing recognition of its medicinal value has heightened harvesting pressure on wild populations, signaling that traditional use is active and widespread enough to pose ecological sustainability concerns.”Traditional Medicine
Scientific Research
The current evidence base for Albizia anthelmintica consists exclusively of in vitro phytochemical characterization studies and in vivo rodent pharmacological models, with no published human clinical trials, randomized controlled trials, or systematic reviews identified in the available literature. Antibacterial studies employ disc diffusion and broth microdilution assays against a panel of clinically relevant bacteria, with MIC values as low as 0.625 mg/mL for chloroform root extract against Salmonella enterica, while antioxidant studies use DPPH, FRAP, and phosphomolybdenum assays to quantify radical scavenging capacity. The most pharmacologically informative animal studies tested aqueous ethanol leaf extracts at 200 and 400 mg/kg in carrageenan-induced edema and acetic acid-induced writhing models in rats, reporting statistically compared outcomes against diclofenac and aspirin as positive controls, though sample sizes per group are not explicitly quantified in available summaries. The evidence quality is therefore preliminary (preclinical only), and extrapolation to human therapeutic dosing, bioavailability, or efficacy is not scientifically justified at this time.
Preparation & Dosage
Traditional preparation
**Traditional Decoction (Bark/Root)**
Bark or root pieces are boiled in water to prepare a decoction administered orally for anthelmintic and antibacterial purposes in East African traditional practice; specific volumes and concentrations are not standardized in the ethnobotanical literature.
**Aqueous Ethanol Extract (Research Form)**
200–400 mg/kg in rats) and analgesic activity and represents the best-characterized preparation
Laboratory studies use 70% aqueous ethanol maceration of dried leaf, bark, or root material; this is the form most associated with anti-inflammatory (.
**Chloroform/Hexane Fractions (Research Form)**
625 mg/mL against S
Chloroform root extracts achieve the lowest MIC values in antibacterial testing (0.. enterica); these non-polar fractions concentrate terpenoids and other lipophilic bioactives but have no established human dose.
**Animal Research Dosing (Non-Extrapolatable)**
400 mg/kg body weight for aqueous ethanol leaf extract; direct extrapolation to human doses is not validated — a rough allometric scaling to a 70 kg human would suggest hundreds of milligrams to several grams, but this is speculative without clinical pharmacokinetic data
Effective doses in rat models range from 200 to .
**Standardization**
No commercial standardized extract exists; no established marker compound percentage or phytochemical specification has been adopted for quality control purposes.
**Timing and Administration Notes**
Traditional use is typically acute and short-term for parasite clearance; no chronic dosing regimens, cycling protocols, or timing recommendations are supported by research data.
Nutritional Profile
Albizia anthelmintica is not used as a food or dietary staple and has not been subjected to proximate nutritional analysis; consequently, no data exist for macronutrient (protein, carbohydrate, fat) or micronutrient (vitamins, minerals) composition. Its phytochemical profile is well-characterized in roots, bark, and leaves, with roots containing the highest total phenolic content (1741.08 ± 0.05 mg gallic acid equivalents/100 g dry weight) and total flavonoid content (366.80 ± 0.02 mg quercetin equivalents/100 g dry weight). Specific identified compounds include gallic acid, quercetin, kaempferol, quercetin-3-O-β-D-glucopyranoside, kaempferol-3-O-β-D-glucopyranoside, quercetin-3-O-(6''-O-galloyl-β-D-glucopyranoside), kaempferol-3-O-(6''-O-galloyl-β-D-glucopyranoside), and quercetin-3-O-β-galactopyranoside, alongside alkaloids, saponins, diterpenes, terpenoids, tannins, quinones, and fatty acids detected via phytochemical screening. Bioavailability of these compounds has not been assessed through pharmacokinetic studies in any species, and the impact of traditional aqueous preparation methods on extraction efficiency and compound stability is unknown.
How It Works
Mechanism of Action
The antioxidant mechanism of Mkoba extracts is primarily attributed to the hydrogen atom transfer and single electron transfer capacity of phenolic hydroxyl groups present in gallic acid, quercetin, kaempferol, and their glucoside and galloylglucoside conjugates, as confirmed via DPPH, ferric reducing antioxidant power (FRAP), and phosphomolybdenum assays; however, intracellular pathway modulation such as Nrf2-ARE activation has not been directly investigated. Antibacterial activity is mechanistically attributed to tannin-induced protein precipitation and membrane permeabilization, terpenoid interference with bacterial enzyme systems, and saponin disruption of phospholipid bilayer integrity, collectively impairing bacterial viability across a broad pathogen spectrum. The anti-inflammatory and analgesic effects observed in carrageenan rat models are consistent with prostaglandin synthesis inhibition — plausibly via COX-1/COX-2 enzyme modulation by quercetin and kaempferol, both of which are documented COX inhibitors in other species — though direct COX binding assays, receptor occupancy studies, or gene expression profiling have not been performed for this species. The anthelmintic activity traditionally ascribed to the plant is hypothesized to involve saponin-mediated disruption of helminth teguments and alkaloid interference with neuromuscular function in parasites, but no published molecular or parasitological mechanistic studies exist for A. anthelmintica specifically.
Clinical Evidence
No human clinical trials have been conducted for Albizia anthelmintica in any indication, including its primary traditional application as an anthelmintic. The entirety of controlled pharmacological data derives from rodent models demonstrating dose-dependent anti-inflammatory effects (37.87–44.35% edema inhibition at 200–400 mg/kg) and analgesic effects (52.44–76.83% protection at the same doses), with comparisons to standard pharmaceutical agents suggesting moderate but sub-maximal efficacy relative to diclofenac and aspirin. These animal findings, while internally consistent and supported by plausible phytochemical mechanisms, cannot be directly translated to human dosing or efficacy claims without pharmacokinetic bridging studies, dose-scaling methodologies, and first-in-human safety data. Confidence in clinical outcomes for human use is currently very low, and the ingredient should be regarded strictly as a research-stage botanical with ethnopharmacological interest rather than a clinically validated therapeutic.
Safety & Interactions
No formal toxicological studies — including acute toxicity, subchronic toxicity, genotoxicity, or carcinogenicity assessments — have been published for Albizia anthelmintica, meaning the safety profile is essentially uncharacterized and caution is warranted for any human use. The presence of alkaloids in root and bark fractions raises theoretical concern for hepatotoxicity and neurotoxicity at high doses, consistent with alkaloid-containing plants in general, while the high saponin content may cause gastrointestinal irritation (nausea, vomiting, diarrhea) particularly with oral aqueous decoctions, though these risks have not been empirically tested in this species. No drug interaction data exist; however, given that quercetin and kaempferol — two major constituents — are known inhibitors of CYP3A4 and P-glycoprotein in other contexts, theoretical pharmacokinetic interactions with anticoagulants, immunosuppressants, and narrow-therapeutic-index drugs cannot be excluded. No safety guidance for pregnancy, lactation, pediatric use, or individuals with hepatic or renal impairment can be provided based on current evidence, and self-administration beyond traditional supervised use is not recommended until formal safety studies are completed.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Albizia anthelminticaMkobaAlbizia anthelmintica Brongn.MkilifiWormbark albiziaAlbizia anthelmintica (Fabaceae)
Frequently Asked Questions
What is Mkoba (Albizia anthelmintica) traditionally used for?
Mkoba is traditionally used across Tanzania, Kenya, and Ethiopia primarily as an anthelmintic — a treatment to expel intestinal parasites — in both humans and livestock, with bark and root decoctions administered orally by traditional healers. The tree is also employed in traditional practice for its antibacterial properties against infections, and its Swahili name directly references its parasite-expelling function.
Has Albizia anthelmintica been tested in human clinical trials?
No human clinical trials have been conducted for Albizia anthelmintica in any condition as of the current available literature. All controlled pharmacological evidence comes from in vitro cell and bacteria assays and in vivo rodent models, meaning no safe or effective human dose has been established through clinical research.
What are the main bioactive compounds in Mkoba leaves and roots?
Mkoba leaves contain specifically identified polyphenols including gallic acid, quercetin, kaempferol, quercetin-3-O-β-D-glucopyranoside, and kaempferol-3-O-β-D-glucopyranoside, along with their galloylated derivatives. Roots show the highest concentration of total phenolics (1741.08 mg GAE/100 g) and flavonoids (366.80 mg QE/100 g), alongside alkaloids, saponins, diterpenes, terpenoids, and tannins detected across all plant parts.
Is Mkoba (Albizia anthelmintica) safe to use?
The safety of Mkoba has not been formally evaluated in any published toxicology study, meaning no established safe dose, toxicity threshold, or drug interaction profile exists. The presence of alkaloids and saponins in the plant raises theoretical concerns for gastrointestinal irritation and potential liver effects at high doses, and use during pregnancy or lactation is not supported by any safety data.
How does Albizia anthelmintica compare to conventional anti-inflammatory drugs in research?
In rat carrageenan-induced paw edema models, aqueous ethanol leaf extract at 400 mg/kg inhibited inflammation by 44.35%, compared to 54.80% inhibition by the reference drug diclofenac at its tested dose, suggesting moderate but sub-maximal anti-inflammatory activity. Analgesic protection reached 76.83% at 400 mg/kg versus aspirin as a reference comparator, though these are animal model findings and cannot be directly extrapolated to human clinical equivalence.
What is the antioxidant strength of Mkoba compared to common antioxidant supplements?
Mkoba root extracts demonstrate exceptionally potent antioxidant activity with a DPPH IC50 of 0.018 mg/mL, making it one of the most powerful free radical scavengers tested in herbal research. This potency is largely attributed to its high total phenolic content of 1741.08 mg GAE/100g in roots and the presence of quercetin-3-O-β-D-glucopyranoside, an isolated compound with its own IC50 of 12.41 µg/mL. Such antioxidant capacity suggests Mkoba may offer robust protection against oxidative stress, comparable to or exceeding many commercially available antioxidant supplements.
Which part of the Albizia anthelmintica plant contains the most bioactive compounds?
The roots of Mkoba are the most potent source of bioactive compounds, containing the highest total phenolic content at 1741.08 mg GAE/100g and demonstrating superior antioxidant activity with an IC50 of 0.018 mg/mL. While leaf and bark extracts also show antioxidant and anti-inflammatory properties, root extracts consistently outperform these other plant parts in laboratory assessments. Traditional preparations often emphasize the roots for this reason, aligning with modern phytochemical research findings.
Does the form of Mkoba extraction affect its antioxidant and anti-inflammatory potency?
Yes, extraction method significantly impacts Mkoba's bioactivity—aqueous extracts and solvent-based extractions yield different concentrations of phenolic compounds and isolated bioactive molecules like quercetin-3-O-β-D-glucopyranoside. Root extracts have been shown to deliver superior antioxidant IC50 values compared to leaf or bark preparations, suggesting that both plant part selection and extraction methodology directly influence therapeutic efficacy. The solubility of phenolic compounds in different extraction media means that standardized or concentrated extracts may deliver more predictable antioxidant and anti-inflammatory benefits than simple whole-plant preparations.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w mkoba-albizia-anthelmintica curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
